You're scrolling LinkedIn at 11 PM, and another AstraZeneca job post flies by. "Clinical Research Associate — Oncology, Bengaluru." You pause. The salary range catches your eye: ₹4.5-6 LPA for freshers. But here's what stops you cold — the posting mentions "ADC clinical trials." You've heard the term antibody-drug conjugate in your M.Pharm lectures, but you have no idea why AstraZeneca is suddenly hiring for it, or whether you're even qualified. Let me tell you exactly what just changed, and why the next 90 days could define your pharma career trajectory.
On May 25, 2026, the FDA approved Datroway (datopotamab deruxtecan) for first-line triple-negative breast cancer. This isn't just another drug approval. AstraZeneca and Daiichi Sankyo just beat Gilead to market in a three-way race for TROP2-targeted therapies, and the ripple effects are creating thousands of jobs across India's pharma ecosystem right now. If you're a B.Pharm or M.Pharm graduate wondering how to break into oncology drug development, this approval is your opening. I'm going to show you exactly which companies are hiring, what roles are available to freshers, what salaries you can expect, and how to position yourself so that recruiters actually respond to your applications.
I remember when I was starting out in clinical research over a decade ago. Back then, monoclonal antibodies were the hot new thing. Today, antibody-drug conjugates have taken that crown, and the companies developing them are hiring aggressively. Let me break down what just happened, why it matters, and exactly how you can position yourself for this wave.
What Just Happened: AstraZeneca-Daiichi Beat Gilead to First-Line TNBC
On May 25, 2026, the FDA approved Datroway (datopotamab deruxtecan) for first-line treatment of triple-negative breast cancer. This drug is the result of a partnership between AstraZeneca and Daiichi Sankyo, and it beat Gilead to market in what has become a three-way race among TROP2-targeted therapies.
Let me explain why this matters in simple terms. Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer. It lacks the three receptors that most breast cancer treatments target — estrogen receptor (ER), progesterone receptor (PR), and HER2. This means patients have historically had very limited options. For years, chemotherapy was essentially the only first-line treatment. Now, Datroway offers these patients a targeted therapy option from day one of their treatment journey.
Datroway is a TROP2-targeted antibody-drug conjugate. TROP2 (trophoblast cell-surface antigen 2) is a protein that is overexpressed on the surface of many cancer cells, including TNBC cells. By targeting this protein, the drug can deliver its chemotherapy payload — a topoisomerase I inhibitor derived from DXd (deruxtecan) — directly to cancer cells while sparing healthy tissue. This is the fundamental promise of ADC technology, and Datroway's approval validates that this approach works in the most challenging cancer settings.
The timing of this approval is particularly significant. Just this week, Merck and Kelun-Biotech reported triple phase 3 wins for their ADC candidate sac-TMT (sacituzumab tirumotecan). Gilead's trodelvy (sacituzumab govitecan), another TROP2-targeted ADC, has been on the market since 2020 but only for second-line TNBC. AstraZeneca's first-line approval gives them a significant competitive advantage, and that translates directly into hiring. When a company wins a major approval, they need to scale up manufacturing, expand clinical trial operations for next-generation candidates, and build out regulatory and pharmacovigilance teams to support the commercial product. All of this creates jobs.
The ADC space is heating up rapidly, and the companies that are winning are hiring to support their expanding pipelines. AstraZeneca alone has six ADC candidates in clinical development as of 2026. Each one of those programs needs clinical research associates to monitor trials, regulatory affairs specialists to prepare submissions, pharmacovigilance professionals to track safety signals, and medical writers to document everything. If you position yourself correctly, one of those jobs could be yours.
What Are ADCs and Why Are They the Hottest Area in Pharma Right Now?
If you want to work in oncology drug development, you need to understand what an antibody-drug conjugate actually is. Let me break it down without the jargon.
Think of an ADC as a guided missile. The antibody component is like the guidance system. It recognizes and binds to a specific protein on cancer cells — in Datroway's case, that's TROP2. The drug component is the warhead. It is typically a highly potent chemotherapy agent that would be too toxic to give on its own. For Datroway, that's a topoisomerase I inhibitor derived from DXd. The linker is what connects the two, and it is designed to release the drug only after the antibody has delivered it inside the cancer cell.
The result is a therapy that can deliver chemotherapy directly to cancer cells while minimizing damage to healthy tissue. This is why ADCs have become the hottest area in oncology drug development. They combine the targeting precision of biologics with the cell-killing power of chemotherapy.
The market numbers tell the story. The global ADC market was valued at approximately $7.4 billion in 2023 and is expected to exceed $15 billion by 2030, growing at a compound annual rate of over 20 percent. This growth is driving massive hiring across the drug development value chain, from R&D scientists designing new ADCs to clinical research associates monitoring trials to regulatory affairs specialists preparing submissions.
In India, several major players are investing heavily in ADC capabilities. AstraZeneca has a significant R&D presence in Bengaluru that supports their global oncology portfolio, including ADC development. Biocon Biologics has been expanding its ADC manufacturing capabilities, recognizing that contract manufacturing for ADCs is a high-growth opportunity. Syngene International, also based in Bengaluru, provides ADC contract research services to global pharma companies, including analytical development and process optimization for ADC manufacturing.
The CRO sector is equally active. Every major ADC program needs clinical trial support, and CROs like IQVIA, Parexel, ICON, and Syneos Health are running ADC trials across India. These trials need clinical research associates, data managers, regulatory specialists, and pharmacovigilance professionals. Many of these roles are open to freshers who demonstrate genuine interest in oncology.
Here's what most freshers don't realize: ADC development is technically complex, which means companies are willing to train people who show aptitude and interest. The linker chemistry, the conjugation process, the unique toxicity profiles — these are specialized areas where even experienced professionals need training. If you can demonstrate that you've taken the time to understand ADC technology, you immediately become more attractive than candidates with generic pharma backgrounds.
Which Companies Are Hiring for ADC Drug Development in India?
Let me give you a concrete list of companies where you should be looking for ADC-related roles right now, with specific job titles, salary ranges, and application strategies.
AstraZeneca India has a significant presence in Bengaluru, where they run clinical research and regulatory affairs operations supporting their global oncology portfolio. With Datroway now approved and more ADC candidates in their pipeline (including datopotamab deruxtecan combinations and next-generation TROP2 ADCs), they will need clinical research associates to monitor trials and regulatory affairs specialists to support ongoing submissions. The AstraZeneca India careers page is worth checking weekly. Entry-level CRA roles typically start around ₹4 to 6 LPA, while regulatory affairs associate positions can range from ₹4 to 7 LPA depending on your qualifications. Look for postings titled "Clinical Research Associate — Oncology" or "Regulatory Affairs Associate —